Hydromorphone: Dose, Frequency, Indications, Interactions & more

Dosage and Frequency:

  • Initial Dose: The usual starting dose for hydromorphone in tablet form is 2 mg to 4 mg every 4 to 6 hours as needed for pain relief.
  • Titration: Dosage adjustments should be made based on the individual’s response to the medication and the severity of pain.
  • Extended-Release Formulation: Extended-release formulations may require less frequent dosing, typically every 12 hours.

Route of Administration (ROA):

  • Oral: Hydromorphone is available in tablet form for oral administration.
  • Parenteral: It can also be administered intravenously or intramuscularly for rapid pain relief, especially in acute care settings.

Mechanism of Action (MOA):

  • Hydromorphone is a potent opioid analgesic that acts on the central nervous system by binding to opioid receptors in the brain and spinal cord.
  • By activating these receptors, hydromorphone modulates pain perception and alters the emotional response to pain.

Pharmacokinetics (PK) and Pharmacodynamics (PD):

  • Absorption: Hydromorphone is well-absorbed orally, with peak plasma concentrations reached within 30 to 60 minutes.
  • Distribution: It distributes rapidly into tissues and crosses the blood-brain barrier, leading to its analgesic effects.
  • Metabolism: Hydromorphone undergoes hepatic metabolism primarily via glucuronidation.
  • Elimination: The metabolites are primarily excreted in the urine.

Pathophysiology:

  • Hydromorphone acts on opioid receptors located throughout the central nervous system, including the brain and spinal cord.
  • By binding to these receptors, it inhibits the transmission of pain signals and alters the perception of pain.

Indications:

  • Hydromorphone is indicated for the management of moderate to severe pain, such as pain associated with surgery, trauma, or cancer.

Contraindications:

  • Respiratory Depression: Avoid use in patients with severe respiratory depression or compromised respiratory function.
  • Hypersensitivity: Patients with a known hypersensitivity to hydromorphone or other opioids should not use this medication.

Drug Interactions:

  • Central Nervous System Depressants: Concurrent use of other CNS depressants, such as benzodiazepines or alcohol, may potentiate respiratory depression and sedation.
  • Monoamine Oxidase Inhibitors (MAOIs): Concurrent use of hydromorphone with MAOIs may result in serotonin syndrome or hypertensive crisis.

Precautions:

  • Respiratory Depression: Monitor respiratory function closely, especially during initiation of therapy and dosage titration.
  • Dependency and Tolerance: Prolonged use may lead to physical dependence and tolerance, requiring careful dose adjustments and monitoring.
  • Hypotension: Use with caution in patients with hypotension or shock, as hydromorphone may further lower blood pressure.

Monitoring:

  • Monitor vital signs, including respiratory rate and blood pressure, regularly during treatment with hydromorphone.
  • Assess pain intensity and response to medication to guide dosage adjustments and ensure adequate pain control.

Laboratory Tests:

  • Periodic monitoring of liver function tests and renal function may be warranted in patients on long-term hydromorphone therapy.
  • Urine drug screening may be performed to monitor for compliance and detect any potential misuse or abuse of opioids.